US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

49.04

+0.83001.72%

Volume:13.31K

Turnover:655.18K

Market Cap:1.58B

PE:-16.41

High:50.16

Open:48.70

Low:48.64

Close:48.21

52wk High:50.16

52wk Low:13.36

Shares:32.26M

Float Shares:21.62M

Volume Ratio:1.35

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:4.76

PE(LYR):-15.65

Loading ...

Overview Company News Filings

LB Pharmaceuticals shareholders elect Class I directors at annual meeting

H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)

LB Pharmaceuticals to Participate in Upcoming June Investor Events

Eight new option listings and one option delisting on May 28th

Lb Pharmaceuticals Inc : Clear Street Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS

LB Pharmaceuticals initiated with a Buy at Clear Street

LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential

LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital

LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)

LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate

Benzinga Earnings

LB Pharmaceuticals Q1 FY26 net loss widens to $19.1 million

Press Release: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

LB Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates Coverage on LB Pharmaceuticals With Buy Rating, $45 Price Target

MT Newswires Live

LB Pharmaceuticals initiated with a Buy at H.C. Wainwright

LB Pharmaceuticals announces annual shareholder meeting

Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST)

Piper Sandler Reaffirms Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

LB Pharma publishes positive Phase 2 LB-102 schizophrenia trial results in JAMA Psychiatry

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LBRX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":49.04,"timestamp":1787665380599,"preClose":48.21,"halted":0,"volume":13308,"delay":0,"changeRate":0.01721634515660648,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Trading","change":0.83,"latestTime":"08-25 09:43:25 EDT","open":48.7,"high":50.16,"low":48.64,"amount":655183.64802,"amplitude":0.031529,"askPrice":49.55,"askSize":102,"bidPrice":48.37,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":48.21,"preHourTrading":{"tag":"盘前","latestPrice":49.99,"preClose":48.21,"latestTime":"09:04 EDT","volume":7,"amount":343.49,"timestamp":1787663087050,"change":1.78,"changeRate":0.036922,"amplitude":0.030906},"postHourTrading":{"tag":"盘后","latestPrice":48.21,"preClose":48.21,"latestTime":"19:30 EDT","volume":1229,"amount":59262.11,"timestamp":1787614207179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.347415,"impliedVol":0.6311,"impliedVolPercentile":0.3443},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":1.347415,"shares":32259175,"dividePrice":0,"high":50.16,"amplitude":0.031529,"preClose":48.21,"low":48.64,"week52Low":13.36,"pbRate":"4.76","week52High":50.16,"institutionHeld":0,"latestPrice":49.04,"committee":-0.004926,"eps":-2.988,"divideRate":0,"volume":13308,"delay":0,"ttmEps":-2.988,"open":48.7,"prevYearClose":22.26,"prevWeekClose":47.62,"prevMonthClose":40.08,"prevQuarterClose":32.455,"fiveDayClose":48.77,"twentyDayClose":34.94,"sixtyDayClose":27.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1784779200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-08-24","current":-16.134538,"percent":0.797468,"low":-37.407457,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"high":-0.410019,"avg":-24.312143,"sd":7.577604,"marketCap":1536181913},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-24","current":-17.928248,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"marketCap":1536181913}],"updateTime":1787655945225},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642492028","title":"LB Pharmaceuticals shareholders elect Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642492028","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642492028?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:06","pubTimestamp":1781035584,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals held its annual shareholder meeting on June 3, 2026.Shareholders backed the selection of three Class I directors for new three-year terms running to the 2029 annual meeting.Investors ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9jWPkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435705","title":"H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435705?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:35","pubTimestamp":1780940148,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639616388","title":"LB Pharmaceuticals to Participate in Upcoming June Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2639616388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639616388?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"NEW YORK, May  28, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303247/0/en/LB-Pharmaceuticals-to-Participate-in-Upcoming-June-Investor-Events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4233","LBRX","BK4213","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639830697","title":"Eight new option listings and one option delisting on May 28th","url":"https://stock-news.laohu8.com/highlight/detail?id=2639830697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639830697?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:56","pubTimestamp":1779983818,"startTime":"0","endTime":"0","summary":"New option listings for May 28th include Cantor Equity Partners II Inc (CEPT), DESTINY TECH100 INC (DXYZ), LB Pharmaceuticals Inc (LBRX), MapLight ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eight-new-option-listings-and-one-option-delisting-on-may-28th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eight-new-option-listings-and-one-option-delisting-on-may-28th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UFO","DXYZ","CEPT","BK4615","BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638750122","title":"Lb Pharmaceuticals Inc : Clear Street Initiates Coverage With Buy Rating; Price Target $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2638750122","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638750122?lang=en_us&edition=fundamental","pubTime":"2026-05-27 18:51","pubTimestamp":1779879102,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638523876","title":"LB Pharmaceuticals initiated with a Buy at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2638523876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638523876?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:47","pubTimestamp":1779828442,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The firm is citing its “...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","BK4233","LBRX","LB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638951542","title":"LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2638951542","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638951542?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:35","pubTimestamp":1779791723,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $45.00. Ram Selvaraju has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lb-pharmaceuticals-buy-rating-reiterated-45-price-target-maintained-on-lb-102-late-stage-pipeline-and-multi-billion-dollar-sales-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lb-pharmaceuticals-buy-rating-reiterated-45-price-target-maintained-on-lb-102-late-stage-pipeline-and-multi-billion-dollar-sales-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","SSI","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636014748","title":"LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2636014748","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636014748?lang=en_us&edition=fundamental","pubTime":"2026-05-18 07:40","pubTimestamp":1779061205,"startTime":"0","endTime":"0","summary":"Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a Buy rating on the shares post the Q1 report. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-price-target-raised-to-37-from-31-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-price-target-raised-to-37-from-31-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635252212","title":"LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635252212","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635252212?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:46","pubTimestamp":1778622391,"startTime":"0","endTime":"0","summary":"“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next three years that have the pote...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q1-eps-67c-consensus-67c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q1-eps-67c-consensus-67c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223322","title":"LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223322","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223322?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:06","pubTimestamp":1778620008,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 95.47 percent increase over losses of $(14.79) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52508924/lb-pharmaceuticals-q1-eps-0-67-beats-0-75-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247446","title":"LB Pharmaceuticals Q1 FY26 net loss widens to $19.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247446?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616625,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals posted a net loss of $19.1 million for first-quarter 2026, widening from $5.3 million a year earlier, as operating loss deepened to $22.1 million from $6.43 million.R&D expense climbed to $14.6 million from $3.4 million, due to higher clinical trial costs tied to LB-102 studies in bipolar 1 depression and acute schizophrenia, alongside higher production and personnel spending.G&A expense rose to $7.5 million from $3 million, driven by higher headcount, stock-based compensation, and professional fees.Cash, cash equivalents, and marketable securities increased to $365.6 million as of March 31, 2026, with runway expected into Q2 2029.Initiated Phase 3 NOVA-2 in schizophrenia with topline data expected in second-half 2027, started Phase 2 ILLUMINATE-1 in bipolar 1 depression with data expected in Q1 2028, and reiterated plans to begin a Phase 2 adjunctive MDD trial in early 2027 with data expected in first-half 2029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8PqpLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","BK4585","BK4007","LBRX","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635237247","title":"Press Release: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635237247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635237247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression. Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association  Psychiatry. Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder  in early 2027. Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","BK4007","LB","BK4213","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630399509","title":"This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2630399509","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630399509?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:08","pubTimestamp":1777291680,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/27/Morgan-Stanley-strategist-Denny-Galindo-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/27/Morgan-Stanley-strategist-Denny-Galindo-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/52058957/this-lb-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/52058957/this-lb-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4213","BLSX","BLSG","LBRX","BK4233","BK4007","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395876","title":"LB Pharmaceuticals Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395876?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:26","pubTimestamp":1777289160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 07:26 ET (11:26 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LBRX","BK4233","BK4007","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630288393","title":"HC Wainwright Initiates Coverage on LB Pharmaceuticals With Buy Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2630288393","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630288393?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:21","pubTimestamp":1777288907,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc (LBRX) has an average rating of Buy and mean price target of $44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630367577","title":"LB Pharmaceuticals initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2630367577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630367577?lang=en_us&edition=fundamental","pubTime":"2026-04-27 18:17","pubTimestamp":1777285037,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The company is focused on the neuropsychiatr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","LBRX","BK4007","LB","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629319868","title":"LB Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629319868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629319868?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:12","pubTimestamp":1776975145,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals scheduled annual shareholder meeting for June 3, 2026 via virtual webcast.Shareholders set to vote on election of three Class I directors, with terms running to 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL3l8Q0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629859974","title":"Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629859974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629859974?lang=en_us&edition=fundamental","pubTime":"2026-04-24 00:10","pubTimestamp":1776960640,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lb-pharmaceuticals-inc-lbrx-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lb-pharmaceuticals-inc-lbrx-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345774631.USD","LBRX","BK4137","LABU","IE00BFXG0V08.USD","LU0012050646.USD","IE00B64QTZ34.USD","LU0106261612.USD","BK4121","BK4213","LB","BK4581","XBI","XLV","BK4585","BK4233","LU0128526141.USD","WST","HCSG","IE00BYQQ9H92.USD","BK4588","LU0029874061.USD","BK4567","BK4007","BK4504","LU0345774391.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629582836","title":"Piper Sandler Reaffirms Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629582836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629582836?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:40","pubTimestamp":1776944426,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on LB Pharmaceuticals, Inc., with a price target of $78.00. R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629027227","title":"LB Pharma publishes positive Phase 2 LB-102 schizophrenia trial results in JAMA Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2629027227","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629027227?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:07","pubTimestamp":1776888438,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals published Phase 2 NOVA-1 trial results for once-daily oral LB-102 in JAMA Psychiatry; findings were first presented in early 2025.Trial showed LB-102 improved symptoms versus placebo, with rapid onset and sustained benefit through study end.Safety profile was described as favorable, with low rates of movement-related side effects, minimal sedation, and limited gastrointestinal issues.Pivotal Phase 3 NOVA-2 trial in acute schizophrenia is ongoing; topline results expected in second half of 2027.NOVA-2 is designed to enroll about 460 patients across 25 US sites, positioning LB-102 for a pre-NDA FDA meeting if results are positive.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2FTTFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","LBRX","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","BK4007","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":83,"code":"91000000","status":"200"}]}}